These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31259775)

  • 1. Development of an inhibitor in a child with severe hemophilia B: treatment with immunosuppression and an extended desensitization protocol.
    Roberts JC; Jesudas R; Tarantino MD
    Blood Coagul Fibrinolysis; 2019 Sep; 30(6):291-294. PubMed ID: 31259775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication of factor IX neutralizing and anaphylactic inhibitors in a patient with severe haemophilia B using cyclophosphamide immune suppression and factor IX desensitization.
    Greenmyer JR; Grindeland CJ; Kobrinsky NL
    Haemophilia; 2020 Mar; 26(2):e51-e54. PubMed ID: 31961035
    [No Abstract]   [Full Text] [Related]  

  • 4. Factor IX antibody and immune tolerance.
    Warrier I
    Vox Sang; 1999; 77 Suppl 1():70-1. PubMed ID: 10529693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review.
    Bon A; Morfini M; Dini A; Mori F; Barni S; Gianluca S; de Martino M; Novembre E
    Ital J Pediatr; 2015 Feb; 41():12. PubMed ID: 25887512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management of hemophilia patients with inhibitors.
    Nilsson IM
    Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
    [No Abstract]   [Full Text] [Related]  

  • 7. Alloantibodies in hemophilia B binding to multiple factor IX epitopes.
    Thompson AR
    Thromb Res; 1987 Apr; 46(1):169-74. PubMed ID: 2438804
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune tolerance induction and the treatment of hemophilia. Malmö protocol update.
    Berntorp E; Astermark J; Carlborg E
    Haematologica; 2000 Oct; 85(10 Suppl):48-50; discussion 50-1. PubMed ID: 11187871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune tolerance therapy for haemophilia.
    Ho AY; Height SE; Smith MP
    Drugs; 2000 Sep; 60(3):547-54. PubMed ID: 11030466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.
    Boylan B; Rice AS; Neff AT; Manco-Johnson MJ; Kempton CL; Miller CH;
    J Thromb Haemost; 2016 Oct; 14(10):1931-1940. PubMed ID: 27501440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
    Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful multi-modal immune tolerance induction for factor IX deficiency with inhibitors and allergic reactions.
    Kuhn J; Noda C; Massey GV
    Haemophilia; 2018 May; 24(3):e133-e136. PubMed ID: 29600592
    [No Abstract]   [Full Text] [Related]  

  • 13. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis.
    DiMichele D; Kroner B;
    Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 15. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
    Astermark J
    Haemophilia; 2006 Jul; 12 Suppl 3():52-60. PubMed ID: 16683997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful induction of immune tolerance with FIX recombinant in a patient with haemophilia B with inhibitor.
    Soto I; Vicente JM; Corte JR; Urgellés MF; Pinto CR
    Haemophilia; 2004 Jul; 10(4):401-4. PubMed ID: 15230957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regimens of factor VIII administration--continuous infusion vs. bolus.
    Berntorp E
    Haematologica; 2000 Oct; 85(10 Suppl):69-71; discussion 71-2. PubMed ID: 11187875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of immunosuppression in a severe haemophilia B patient with specific antibody.
    Allain JP; Frommel D
    Thromb Haemost; 1976 Aug; 36(1):86-9. PubMed ID: 1036830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure: progress report.
    Barnes C; Brewin T; Ekert H
    Haemophilia; 2001 Jul; 7(4):439-40. PubMed ID: 11442653
    [No Abstract]   [Full Text] [Related]  

  • 20. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure.
    Barnes C; Rudzki Z; Ekert H
    Haemophilia; 2000 Nov; 6(6):693-5. PubMed ID: 11122398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.